Market Overview

BioTelemetry Reports Reduction to Medicare Reimbursement for Remote Cardiac Monitoring Services

Related BEAT
30 Stocks Moving In Monday's Pre-Market Session
Jim Cramer Gives His Opinion On BioTelemetry And Enterprise Products Partners

BioTelemetry, Inc. (Nasdaq: BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that the Centers for Medicare and Medicaid Services ("CMS") has published a reduction to the reimbursement for remote cardiac monitoring services effective January 1, 2014. This reduction will impact all providers of remote cardiac monitoring services and will result in a 13.7% decrease to the national reimbursement rate for the MCOT^TM service. If these rates had been in effect for 2013, we estimate that the Company's revenue would have been negatively impacted by approximately 3.8%. 

Posted-In: News


Related Articles (BEAT)

View Comments and Join the Discussion!